The company beat analysts' sales and earnings estimates in the fourth quarter, but is down nearly 2% today. Yep, no satisfaction here.
Humira has had a nice run against Johnson & Johnson
Still, the company posted a mighty fine quarter. Revenue grew 11% with help from Abbott's acquisition of Advanced Medical Optics and its relatively new drug eluting stent Xience, which continues to see double-digit sales growth and has the top spot over rivals Boston Scientific
The company will continue to diversify this year when it closes its acquisition of Solvay, which will add $3 billion in sales. The new drugs and Humira, which isn't dead yet, is expected to help Abbott turn in a solid 13.5% increase in adjusted earnings per share at the midpoint of its $4.20 to $4.25 guidance.
If Abbott continues to hit that kind of growth, year after year, with or without Humira, investors should be very satisfied.
Pfizer is a Motley Fool Inside Value selection. Johnson & Johnson is an Income Investor selection. The Fool owns shares of and has written puts on Medtronic. Try any of our Foolish newsletters today, free for 30 days.